Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Biotechnologia

Ms. Nadia  Dac

Vice President & Chief Commercial Officer

Dr. Pamela Pierce Palmer M.D., Ph.D.

Co-Founder

Dr. Gregory A. Demopulos M.D.

Co-Founder, Chairman, Chief Executive Officer & President

Dr. Catherine A. Melfi Ph.D.

Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems

Mr. Peter B. Cancelmo J.D.

Vice President, General Counsel & Corporate Secretary

Mr. Michael A. Jacobsen

Chief Accounting Officer, Vice President of Finance & Treasurer

Dr. George A. Gaitanaris M.D., Ph.D.

Chief Scientific Officer & Vice President of Science

Mr. Peter W. Williams

Vice President of Human Resources

Dr. Andreas  Grauer M.D.

Vice President & Chief Medical Officer

Nazwa	Kapitalizacja rynkowa
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Omeros Corporation

Omeros Corporation Lista konkurentów

Główni konkurenci